A new USC Leonard Davis School of Gerontology study challenges existing ideas of how buildup of a protein called amyloid beta (Aβ) in the brain…
Lecanemab: It’s an experimental medication that’s been shown in trials to slow cognitive decline in people with Alzheimer’s disease.
Indiana University School of Medicine researchers are studying how the reduction of a gene variant found in the brain’s immune cells could diminish the risk…
Capturing the genetic architecture of Alzheimer’s disease (AD) is challenging because of the complex interplay of genetic and non-genetic factors in its etiology. It has…
After decades of fundamental scientific and drug discovery research, Alzheimer’s disease has remained inscrutable and incurable, with a bare minimum of therapeutic progress. But in…
Do you know the difference between Medicare and Medicaid? How about, in a pinch, how to find a nursing home and research which ones in…
Why do some people develop Alzheimer’s disease and others don’t? What makes one person’s brain healthier than another’s? And what can be done to improve,…
The U.S. Food and Drug Administration’s approval process for the controversial Alzheimer’s drug Aduhelm was “rife with irregularities,” despite lingering doubts about the power of…
A new drug designed to ward off Alzheimer’s is being tested at more than 100 sites around the world, including the University of Pennsylvania.
5α-reductase inhibitors (5-ARIs) are associated with an increased risk for depression but seem not to be associated with dementia, according to a study published online…